← All trials
NCT00473213
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 1999
- Primary completion
- —
- Completion date
- Feb 1, 2004
- First posted
- —
- Last posted
- —
- Enrollment
- 217
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of TurinLead sponsor
- Ospedale Maggiore San Giovanni BoscoOverall official - principal investigator
- Ospedale Civile di ChivassoOverall official - principal investigator
- Ospedale Generale di MacerataOverall official - principal investigator
- Ospedale SAntonio Abate Servizio recupero NeurologicoOverall official - principal investigator
- Istituto Don Carlo Gnocchi Divisione Neurologica Riabilitativa. Via Capecelatro 66 20148 MilanoOverall official - principal investigator
- Azienda Ospedaliera G. BrotzuOverall official - principal investigator
- Ospedale Generale di BolzanoOverall official - principal investigator
- Ospedale S. CroceOverall official - principal investigator
- Policlinico Universitario Centro Sclerosi MultiplaOverall official - principal investigator
- University of FerraraOverall official - principal investigator
- University of BresciaOverall official - principal investigator
- University of PerugiaOverall official - principal investigator
- University of VeronaOverall official - principal investigator
- Dimensione Ricerca s.r.l.Collaborator
- University of MilanOverall official - principal investigator
- University of Modena and Reggio EmiliaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.